Article Text
Abstract
Introduction/Background Survival of women with metastatic brain disease from breast cancer who underwent Whole Brain Radiation Therapy vary from institution to institution and influenced by demographic factors, tumor factors such as the immunohistochemical subtype and their treatment. The objective of the study is to determine the overall survival of Filipino women with metastatic brain disease from breast carcinoma who underwent Whole Brain Radiation Therapy in a cancer institutute in Cebu City from January, 2005 to December, 2016.
Methodology Clinical data of Filipino women with metastatic brain disease from breast cancer who underwent Whole Brain Radiation Therapy were gathered from the cancer institute, medical records, and charts from the clinics of four active oncologists in a tertiary hospital in Cebu. Kaplan-Meier product limit estimate of survival was used to determine the median survival time according to immunohistochemical subtype. The difference on the survival time between variables were tested using Log Rank Test. Cox Regression analysis was done to determine the effects of these variables to the overall survival time.
Results A total of 1573 patients were diagnosed with breast cancer in the said institute from 2005 to 2016, 106 (6.73%) received Whole Brain Radiation Therapy, 61 patients were eligible for analysis. The median time from breast cancer diagnosis to brain metastasis is 43.9 months. The median time from brain metastasis to death is 2.7 months. Overall median survival time is 2.6 months, with ER(+)PR(+)Her2(-) subtype having the longest survival time among the 3 most common subtypes. Independent factors influencing the overal survival are: initial clinical stage, number of brain metastases, hormonal therapy, and chemotherapy after Whole Brain Radiation Therapy.
Conclusion Overall survival time of Filipino women with metastatic brain disease from breast cancer who underwent Whole Brain Radiation Therapy in our institution is 2.6 months.
Disclosure Nothing to disclose.